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Background: Previous studies assessing second primary malignancies (SPMs) after uterine cancer have been
conducted in Western populations with conflicting results. This study aimed to define the incidence and risk of
SPMs in Taiwanese patients with an initial diagnosis of uterine cancer.
Methods: Using population-based data from the Taiwan Cancer Registry for the period 1979–2008, we quantified
standardized incidence ratios (SIRs) among 11,571 women with an initial diagnosis of uterine cancer.
Results: Among the 11,571 women, 555 (4.80 %) developed at least one SPM during 69,987 person-years of follow-up.
There was a 71 % increased risk of SPM following uterine cancer (SIR = 1.71, 95 % CI, 1.57–1.86), with higher risks in the
vagina/vulva (SIR = 9.06), small intestine (SIR = 8.45), ovary (SIR = 4.15), urinary bladder (SIR = 2.31), kidney (SIR = 2.24),
colorectum (SIR = 2.24), lung (SIR = 1.96), and breast (SIR = 1.43). The risk of SPM was found to be the highest within the
first 5 years after diagnosis of uterine cancer, with surveillance bias possibly contributing to the extremely high risk
observed in the first follow-up year. The overall risk and pattern of SPM development observed in this study differed
from those previously reported in Western populations, possibly because of the methodology and shorter follow-up
period employed in this study. The cumulative incidence of SPMs was significantly higher in older patients (≥50 years)
than in younger patients (P < 0.001).
Conclusions: To our knowledge, this is the first study in an Asian population to report 71 % increased risk in SPMs in
women previously diagnosed with uterine cancer. A younger age at diagnosis of uterine cancer conferred an increased
risk of second malignancies, and SPMs worsened survivorship in patients who survived uterine cancer.
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Uterine cancer is the sixth most common malignancy in
women worldwide [1]. In Western countries, it is the
most common gynecological malignancy, with a con-
tinuously rising incidence rate [1-3]. For example, the in-
cidence of endometrial cancer reportedly increased by
21 % from 2008–2012 in the United States [3]. The inci-
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the incidence of uterine cancer has more rapidly in-
creased than other malignancies from 3.43–15.07 per
100,000 between 1996 and 2010 [6, 7]. It is noteworthy
that age at onset of uterine cancer among Asian patients
has been reported to peak at 45–55 years, at least 10–15
years earlier than that reported in Western patients [4].
A similar trend in age at breast cancer diagnosis has
been reported in Asian patients [8]; however, the mecha-
nisms underlying the lower age at onset for both cancers
remain unclear. Further evaluation of the risk of second
primary malignancies (SPMs) following uterine cancer
may provide some insights to its etiology.le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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comprise ~90 % adenocarcinomas, 8 % sarcomas, and
other unspecified types [9, 10]. The 5-year overall sur-
vival rate for uterine cancers recorded in the Surveil-
lance, Epidemiology, and End Results (SEER) database
(1988–2001) was found to be 87.9 %. Of all patients in
this database, 75.3 % had stage I disease, and these pa-
tients had a five-year survival rate of 97.4 % [9]. Consid-
ering the increasing incidence and survival rate of
patients with uterine cancer worldwide, SPMs have be-
come an increasingly important clinical issue. Neverthe-
less, most studies about SPMs after uterine cancer have
been conducted in Western populations [11-18]. The
most comprehensive evaluation of the SEER database
has demonstrated markedly elevated SIRs for several
specific sites; however, the overall SIR was not found to
be increased [19]. Similarly, two large SEER studies
based on 90,502 and 98,205 patients with primary endo-
metrial cancer from 1973–2004 and 1973–2007, respect-
ively, revealed that the overall risk of SPMs did not
differ from the general population [14, 18]. In contrast, a
nationwide Swedish population-based study reported a
54 % increased risk in overall SPMs [13], and other stud-
ies have reported a higher risk of developing SPMs after
uterine cancers in patients with a young age at diagnosis
[17], African ancestry [18], Lynch syndrome (LS), family
history of breast or ovarian cancer [12, 13, 17], and in
those receiving radiotherapy [15, 16].
There are racial disparities in the SEER database [18].
The overall risk of SPMs after endometrial cancer was
found to be higher in Americans of an African descent
(SIR = 1.19; 95 % CI, 1.08–1.31) and lower in Caucasians
(SIR = 0.85; 95 % CI, 0.84–0.87) compared with the gen-
eral population. Furthermore, the pattern of SPMs was
found to differ between African American and Caucasian
populations. Therefore, there is a clinical requirement for
studies assessing SPMs following uterine cancers in Asian
populations, which, to our knowledge, have not been pre-
viously reported. To achieve this objective, we conducted
a retrospective population-based study using a database
from the Taiwan Cancer Registry (TCR) that included a
total of 12,509 patients with an initial diagnosis of uterine
cancer between 1979 and 2008.
Methods
Data sources
We quantified the incidence of SPMs among the 12,509
patients with an initial diagnosis of uterine cancer (Inter-
national Classification of Diseases, 9th Revision (ICD-9)
codes: 179 and 182) reported in TCR (http://crs.cph.ntu.e-
du.tw/) from January 1, 1979–December 31, 2008. This
TCR was founded in 1979 and is financed by the Ministry
of Health and Welfare for estimating the incidence of can-
cer in Taiwan. It is a population-based cancer registry thatcovered 22 million people in 2003. Furthermore, the hos-
pitals with more than 50 beds are required to submit in-
formation regarding patients with newly diagnosed cancer
to TCR, which reimburses the hospitals based on the re-
ported number of cases for reducing the possibility of
under-reporting. All cancer registry databases in TCR have
been systemically converted to ICD-9 codes [20] and
linked with death certificates from the national death data-
base. Therefore, individuals not identified by this process
were considered to be alive for the purpose of the current
study (passive follow-up). Coding of multiple primaries
followed the principles of International Association of
Cancer Registries (IACR) and International Agency for
Research on Cancer (IARC) [21-23]. Informed consent
was not required because all registry records are an-
onymous and accessible to the public. The study was
approved by the Ethics Committee of the Chang Gung
Memorial Hospital.
Since 1996, 80 %–90 % of patients with uterine cancer
have received hysterectomy as the standard treatment in
Taiwan, limiting the risk of secondary cervical cancer [6, 7].
One hundred and three patients with a second cervical can-
cer (ICD-9: 180) were excluded from the analysis as dis-
crimination between cervical cancer, endometrial cancer
extending to the cervix, and cervical recurrence was chal-
lenging in patients who did not receive hysterectomy. Thus,
this study evaluated the risk of secondary non-cervical can-
cers. We aimed to accurately determine the age at onset,
estimate the person-years of follow-up, and minimize po-
tentially unconfirmed cancer diagnoses in this study cohort.
A total of 835 patients were excluded from analysis because
they met one or more of the following criteria: (1) missing
birth date (7 cases); (2) missing follow-up date or death sta-
tus (128 cases); (3) SPM diagnosis or death occurring less
than 1 month after diagnosis of uterine cancer (684 cases);
or (4) age under 20 years (18 cases). Thus, 11,571 patients
were included in the analysis.
Statistical analysis
SIRs and the corresponding 95 % CIs were calculated
[24] for all types of SPMs except for uterine corpus to
quantify the rate of second malignancy development
after diagnosis of uterine cancer. SIRs were calculated as
the ratio of the observed number (O) of SPMs to the ex-
pected number (E), assuming the patients had the same
incidence of cancer as the general female population.
The number of person-years at risk was defined as the
number of years from the date of diagnosis of uterine
cancer to the date of death, date of SPM diagnosis, or
end of the study period (December 31, 2008), whichever
occurred first. The person-years of observation for each
5-year age group, 5-year period (1979–1983, 1984–1988,
1989–1993, 1994–1998, 1999–2003, and 2004–2008),
and the time from entry to the cohort (≤1, 1–5, 5–10, or
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the Taiwanese female population. The corresponding
products were summed over all ages and calendar years
to yield the expected numbers of SPMs at each site. SIR
confidence intervals were based on an assumed Poisson
distribution of SPM cases. An approximate χ2 test was
used for evaluating differences between two SIRs and
trends in SIRs.
Survival curves of patients with uterine cancer diag-
nosed at age <50 and ≥50 years were calculated using
the Kaplan–Meier method. Differences between the two
age groups were examined by the log-rank test. Further,
the Cox model with a time-dependent covariate [25, 26],
allocating follow-up time for each patient to the non-
SPM group until SPM occurrence, was used for compar-
ing the survival between patients with and without SPM.
All statistical tests were two-sided, and a P value of less
than 0.05 was considered statistically significant.
Results
Patient characteristics
Of the 11,571 women with an initial diagnosis of uterine
cancer (4,445 diagnosed at age <50 years and 7,126 at
age ≥50 years) and the complete data available for ana-
lysis, 555 (4.80 %) developed SPM during 69,987 person-
years of follow-up (Table 1). Of all the enrolled patients,
10.47 % were diagnosed with uterine sarcoma, and the
remaining with endometrial cancer. Overall, uterine can-
cer was diagnosed at a mean age of 52.93 years, and the
mean age at SPM diagnosis was 61.23 years. The average
follow-up time was 6.05 years, including 9,638 cases
(83 %) followed up for at least one year, 2,678 (23 %) for
5–10 years, and 2,518 (22 %) for >10 years. The average
interval between the first and second cancers was
6.27 years, with a standard deviation of 5.53 years.
Risk of second primary malignancies stratified by site
SIRs and the corresponding 95 % CIs for SPMs at all
sites, except the uterine corpus, were calculated. Patient
ages at initial uterine cancer and SPM diagnoses are pre-
sented in Table 2. Irrespective of the site, the overall SIRTable 1 Characteristics of population-based cohort of 11,571 patien
1979-2008
No. with uterine cancer
No. who developed a SPM (%)
Average age at diagnosis of uterine cancer ± SD (years)
Average age at diagnosis of SPM ± SD (years)
Average interval between first and second cancers ± SD (years)
Average follow-up (years)
SD standard deviation, SPM second primary malignancy
aAge at uterine cancer diagnosis. An age of 50 years was selected for comparison afor developing SPM was 1.71 (95 % CI, 1.57–1.86). Re-
garding SPM sites, the risk of developing genital malig-
nancies, including ovarian, vaginal, and vulvar, was the
highest (SIR = 4.91; 95 % CI, 3.71–6.37), followed by the
urinary system (SIR = 2.27; 95 % CI, 1.64–3.06) and di-
gestive system (SIR = 1.71; 95 % CI, 1.49–1.96). In par-
ticular, there was an increased risk of vaginal/vulvar
(SIR = 9.06), small intestinal (SIR = 8.45), ovarian (SIR =
4.15), urinary bladder (SIR = 2.31), kidney (SIR = 2.24),
colorectal (SIR = 2.24), lung (SIR = 1.96), and breast
(SIR = 1.43) cancers (Table 2).
Risk of second primary malignancies stratified by age at
diagnosis of uterine cancer
For the eight sites with an increased risk of SPMs, SIRs
were further stratified according to age at diagnosis of
uterine cancer (<50 and ≥50 years, Table 3, left half ).
Overall, patients <50 years at onset had a slightly higher
risk of developing SPM than those aged ≥50 years (SIR =
2.44 vs. 1.98, P = 0.06). The age-based trend was the most
prominent for small intestinal, colorectal, and ovarian
SPMs (P = 0.005, 0.001, and 0.018, respectively), whereas
the risk of lung, breast, vaginal, urinary bladder, and kid-
ney SPMs was similar between age groups.
Risk of second primary malignancies stratified by
follow-up interval
SIRs stratified according to the follow-up interval from
the initial diagnosis of uterine cancer were examined for
the eight sites with an elevated risk of SPM (Table 3,
right half ). The follow-up period was divided into 4 in-
tervals: ≤1, 1–5, 5–10, and ≥10 years. Overall, SIR was
found to markedly decrease over time. The increased
risk of SPM at all selected sites was the greatest in the
first year and diminished with time (SIR = 19.80, 4.39,
1.79, and 0.92 for ≤1, 1–5, 5–10, and ≥10 years follow-
up, respectively, P < 0.001). Furthermore, an increased
risk of breast, ovarian, and bladder SPM was observed in
only the first 5 years, whereas an increased risk of small
intestinal, colorectal, lung, and kidney SPM remained
after up to 10 years of follow-up. The vagina/vulva wasts first diagnosed as uterine cancer (ICD-9: 179, 182) in Taiwan
All <50 years olda ≥50 years olda
11,571 4,445 (38.42 %) 7,126 (61.58 %)
555 (4.80 %) 163 (3.67 %) 392 (5.50 %)
52.93 ± 11.69 41.63 ± 6.22 59.98 ± 8.26
61.23 ± 11.78 48.59 ± 8.57 66.50 ± 8.49
6.27 ± 5.53 6.61 ± 5.68 6.14 ± 5.47
6.05 ± 5.55 7.00 ± 5.84 5.46 ± 5.27
s this is the average menopausal age in Taiwanese women
Table 2 Observed (O) and expected (E) numbers of second primary cancers after diagnosis of an initial uterine cancer (ICD-9 179,
182) in Taiwan 1979-2008
SPM site (ICD-9 code) Age of uterine cancer
(years) (mean ± SD)
Age of SPM (years)
(mean ± SD)
O E SIR (O/E) (95 % CI)
Head and neck 57.89 ± 11.95 63.67 ± 12.94 9 10.51 0.86 (0.39, 1.63)
Oral & pharynx (141, 143-5, 146,148-9) 49.50 ± 5.92 54.25 ± 8.96 4 4.81 0.83 (0.22, 2,13)
Nasopharynx (147) 71.67 ± 8.33 77.00 ± 6.93 3 4.48 0.67 (0.13, 1.96)
Larynx (161) 57 70 1 0.41 2.45 (0.03, 13.64)
Major salivary glands (142) 51 55 1 0.80 1.24 (0.02, 6.92)
Digestive system 56.21 ± 10.12 63.28 ± 10.41 212 124.06 1.71 (1.49, 1.96)
Esophagus (150) 58.00 ± 1.41 65.50 ± 7.78 2 1.57 1.28 (0.14, 4.61)
Stomach (151) 59.92 ± 9.06 66.88 ± 8.59 25 17.09 1.46 (0.95, 2.16)
Small intestine (152) 50.33 ± 10.45 56.50 ± 11.34 12 1.42 8.45 (4.36, 14.77)
Colorectum (153,154) 54.70 ± 10.43 61.22 ± 10.42 119 53.05 2.24 (1.86, 2.68)
Liver (155) 60.16 ± 6.81 69.09 ± 6.72 45 39.42 1.14 (0.83, 1.53)
Biliary system (156) 63.67 ± 15.95 71.67 ± 13.43 3 4.82 0.62 (0.13, 1.82)
Pancreas (157) 48.50 ± 12.57 54.17 ± 12.98 6 6.69 0.90 (0.33, 1.95)
Genital system 49.48 ± 12.52 52.57 ± 13.82 56 11.42 4.91 (3.71,6.37)
Ovary (183) 48.40 ± 11.54 49.75 ± 11.43 40 9.65 4.15 (2.95, 5.64)
Vagina and vulva (184) 52.19 ± 14.75 59.63 ± 16.92 16 1.77 9.06 (5.17, 14.71)
Urinary system 55.95 ± 13.10 64.14 ± 12.18 43 18.94 2.27 (1.64, 3.06)
Urinary bladder (188) 53.89 ± 15.02 62.28 ± 14.42 18 7.79 2.31 (1.37, 3.65)
Kidney (189) 57.44 ± 11.62 65.48 ± 10.38 25 11.16 2.24 (1.45, 3.31)
Lung and bronchus (162) 58.63 ± 10.19 64.97 ± 10.99 72 36.81 1.96 (1.53, 2.46)
Sarcoma (171) 48.50 ± 16.81 52.50 ± 16.45 6 6.77 0.89 (0.32, 1.93)
Skin (173) 52.50 ± 11.57 59.14 ± 12.38 14 11.85 1.18 (0.65, 1.98)
Breast (174) 53.41 ± 10.20 59.23 ± 10.46 95 66.51 1.43 (1.16, 1.75)
Brain (191) 52.00 ± 9.02 54.75 ± 9.25 4 2.25 1.78 (0.48, 4.55)
Thyroid (193) 55.46 ± 10.61 59.77 ± 11.50 13 9.84 1.32 (0.70, 2.26)
Leukemia (204-8) 51.33 ± 7.12 58.00 ± 9.80 9 5.07 1.77 (0.81, 3.37)
Lymphoma (200-3) 61.00 ± 7.62 67.57 ± 6.58 7 8.39 0.83 (0.33, 1.72)
Others 50.27 ± 13.00 56.93 ± 13.80 15 12.54 1.20 (0.67, 1.97)
Total 55.01 ± 11.45 60.54 ± 12.08 555 324.95 1.71 (1.57, 1.86)
Bold denotes statistical significance
SD standard deviation, SIR standardized incidence ratio, SPM second primary malignancy, O observed numbers of SPMs, E expected numbers of SPMs,
CI confidence interval
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lasting for ≥10 years of follow-up.
Cumulative incidence rates of all second cancers
The estimated overall risk of developing SPM in uterine
cancer survivors was calculated, with death treated as a
competing risk. For all SPMs, the cumulative risk in the
younger group (<50 years) at 5, 10, 15, 20, and 25 years
after uterine cancer was estimated to be 1.96 %, 3.85 %,
6.47 %, 9.15 %, and 13.24 %, respectively (Fig. 1). In con-
trast, the cumulative incidence was higher in older pa-
tients (≥50 years) than in younger patients (3.42 %, 6.42 %,10.07 %, 12.84 %, and 20.51 % at 5, 10, 15, 20, and 25 years,
respectively). A significant difference between the two cu-
mulative incidence curves indicated that the risk of all
SPMs differed between age groups (P < 0.001; Fig. 1).
Overall survival and impact of second primary
malignancies in patients with uterine cancer
The median overall survival was 25.08 years, and the
five-year survival rate was 81 % (Fig. 2a). The patients
diagnosed with uterine cancer at an age <50 years had a
higher survival than those diagnosed at a later age
(Fig. 2a, P < 0.001). For the 555 patients with SPMs, the
Table 3 Risk for significant second primary cancers by age at diagnosis of uterine cancer (left half) and follow-up interval (right half),
respectively
SPM site (ICD-9 code) Agea (years) O E SIR (O/E) 95 % CI Intervalb (years) O E SIR (O/E) 95 % CI
Small intestine (152) <50 7 0.27 26.06 (10.44, 53.71) ≤5 6 0.23 25.95 (9.48-56.49)
≥50 5 1.15 4.34 (1.40, 10.14) ≤1 0 0.03 0 NA
1-5 6 0.20 29.47 (10.76-64.15)
5-10 3 0.38 7.97 (1.60-23.30)
≥10 3 0.81 3.69 (0.74-10.79)
Colorectum (153,154) <50 36 9.68 3.72 (2.60, 5.15) ≤5 58 9.00 6.45 (4.89-8.33)
≥50 83 43.36 1.91 (1.52, 2.37) ≤1 12 1.07 11.25 (5.81-19.66)
1-5 46 7.93 5.8 (4.25-7.74)
5-10 29 14.05 2.06 (1.38-2.96)
≥10 32 30.00 1.07 (0.73-1.51)
Lung (162) <50 13 6.24 2.08 (1.11, 3.56) ≤5 36 6.22 5.78 (4.05-8.00)
≥50 59 30.57 1.93 (1.47, 2.49) ≤1 7 0.74 9.42 (3.77-19.40)
1-5 29 5.48 5.29 (3.54-7.59)
5-10 24 9.73 2.47 (1.58-3.67)
≥10 12 20.85 0.58 (0.30-1.01)
Breast (174) <50 34 29.38 1.16 (0.80, 1.62) ≤5 52 13.71 3.79 (2.83-4.97)
≥50 61 37.13 1.64 (1.26, 2.11) ≤1 12 1.40 8.56 (4.42-14.96)
1-5 42 12.31 3.25 (2.32-4.43)
5-10 21 20.05 1.05 (0.65-1.60)
≥10 22 32.75 0.67 (0.42-1.02)
Ovary (183) <50 23 3.68 6.25 (3.96, 9.38) ≤5 37 1.84 20.12 (14.16-27.73)
≥50 17 5.97 2.85 (1.66, 4.56) ≤1 30 0.20 152.87 (103.12-218.25)
1-5 7 1.64 4.26 (1.71-8.78)
5-10 1 2.78 0.36 (0.00-2.00)
≥10 2 5.03 0.40 (0.04-1.44)
Vagina (184) <50 6 0.38 15.68 (5.73, 34.14) ≤5 7 0.29 24.43 (9.79-50.34)
≥50 10 1.38 7.22 (3.46, 13.29) ≤1 6 0.04 172.12 (62.85-374.65)
1-5 1 0.25 3.97 (0.05-22.11)
5-10 3 0.46 6.58 (1.32-19.23)
≥10 6 1.02 5.86 (2.14-12.75)
Bladder (188) <50 5 1.07 4.69 (1.51, 10.95) ≤5 7 1.22 5.74 (2.30-11.82)
≥50 13 6.72 1.93 (1.03, 3.31) ≤1 3 0.15 19.69 (3.96-57.52)
1-5 4 1.07 3.75 (1.01-9.59)
5-10 4 1.99 2.01 (0.54-5.14)
≥10 7 4.58 1.53 (0.61-3.15)
Kidney (189) <50 4 1.68 2.38 (0.64, 6.10) ≤5 7 1.82 3.86 (1.54-7.95)
≥50 21 9.47 2.22 (1.37, 3.39) ≤1 6 0.22 27.70 (10.12-60.30)
1-5 1 1.60 330.63 (0.01-3.48)
5-10 9 2.93 3.07 (1.40-5.82)
≥10 9 6.40 1.41 (0.64-2.67)
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Table 3 Risk for significant second primary cancers by age at diagnosis of uterine cancer (left half) and follow-up interval (right half),
respectively (Continued)
Total <50 128 52.37 2.44 (2.04, 2.91) ≤5 210 34.33 6.12 (5.32,7.00)
≥50 269 135.77 1.98 (1.75, 2.23) ≤1 76 3.84 19.80 (15.60-24.75)
1-5 134 30.50 4.39 (3.68-5.21)
5-10 94 52.37 1.79 (1.45, 2.20)
≥10 93 101.45 0.92 (0.74, 1.12
Bold indicates statistical significance
SIR standardized incidence ratio, SPM second primary malignancy, O observed numbers of SPMs, E expected numbers of SPMs, CI confidence interval
aAge at diagnosis of uterine cancer
bFollow-up interval after the diagnosis of uterine cancer
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(Fig. 2b), with 1–, 5–, 10–, and 15-year survival rates of
74 %, 47 %, 36 % and 28 %, respectively. Of these pa-
tients, the younger age group had a higher survival after
diagnosis of any SPM (median survival time, 10.14 vs.
2.40 years; P < 0.001).
The Cox model with a time-dependent covariate was
employed for assessing the impact of SPMs on survival
(Table 4). After adjusting for age at diagnosis of uterine
cancer, we found that the SPM development was associ-
ated with a markedly increased risk of death (adjusted haz-
ard ratio = 1.74, P < 0.001). This result suggests older
patients (≥50 years) at initial uterine cancer diagnosis who
subsequently develop SPM are at the highest risk of death.
Discussion
Patients in the present study had a median overall sur-
vival of 25.08 years, consistent with the reported survival
of patients in the SEER database. In our study, patientsFig. 1 Cumulative incidence rates of all the second cancers after uterine cawith SPMs had a median survival of 3.77 years following
SPM diagnosis, and the average interval between the
first and second cancers was 6.27 years (SD = 5.53 years).
The highest risk of developing SPM was observed in the
first 5 years after diagnosis of uterine cancer, largely be-
cause of an extremely increased risk in the first year
(Table 3). The close follow-up during the first year fol-
lowing the diagnosis may have contributed to an earlier
detection of second malignancies, leading to a surveil-
lance bias. Moreover, recommendations regarding
screening should consider this observed latency pattern.
Screening and preventive strategies for SPMs are essen-
tial for reducing mortality rates. However, no universal
guidelines for SPM surveillance in patients with uterine
cancer have been established to date. A major obstacle
has been contradictory results from studies examining
SPMs. For example, a nationwide Swedish population-
based study reported a 54 % increased risk for all SPMs
(SIR = 1.54; 95 % CI, 1.48–1.61) in 19,128 patients withncer stratified by age
Fig. 2 (a): Survival of all the patients with uterine cancer stratified by age at diagnosis of uterine cancer; (b): survival after second primary cancers
stratified by age
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of subsequent malignancy at 11 sites, including the
ovary, urinary bladder, small intestine, connective tissue,
colon or rectum, female genitalia, kidney, skin (squa-
mous cell), breast, and bone marrow (particularly,
leukemia). However, the strong decline in SPM develop-
ment with the length of follow-up found in our study
was not observed in the Swedish data [13]. A complete
evaluation of the US SEER data revealed no increase in
the overall risk of SPMs (SIR = 0.99, excluding femalegenital sites; 95 % CI, 0.97–1.01). However, our study
corroborated findings of the SEER database regarding
the association between age at onset and risk of SPM.
Further, despite SIRs being generally lower in the SEER
database than those reported in Taiwan, the same SPM
sites were found to have increased SIRs [19]. Another
study using the SEER database also found no overall in-
creased risk of SPMs (SIR = 0.85; 95 % CI, 0.84–0.87)
and reported no increased risk of breast, ovarian, or
colorectal SPM [18]. In our study, there was a 71 %
Table 4 Cox regression analysis of overall survival, with second
cancer as a time-dependent covariate
Hazard ratio P-value
Age diagnosis age <50 1 <0.001
≥50 2.457
Second cancers without 1 <0.001
with 1.771
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1.71; 95 % CI, 1.57–1.86), with a higher risk of small in-
testinal, colorectal, ovarian, vaginal/vulvar, breast, urin-
ary bladder, kidney, and lung cancers. In general,
treatments for uterine cancer in Taiwan are similar to
those used in Western countries, particularly the US, as
Taiwanese clinicians generally follow American guide-
lines. Hence, the discrepancies in results in this study
and those using the US SEER data may be because of
follow-up time, surveillance bias, and methodology ra-
ther than differences in treatment regimes. First, the
follow-up period in our study (69,987 person-years) was
shorter than that in the US (705,002 person-years) and
Swedish (255,211 person-years) studies [13, 19]. Second,
a close follow-up in the first 5 years, particularly the first
year, may have contributed to an earlier detection of
SPM and lead to surveillance bias. Last, differences may
have been because of the study methodology rather than
intrinsic differences between the two countries. For ex-
ample, the influence of migration on Taiwan is minimal
compared with that on the US. The population in
Taiwan is relatively stable, and mostly, Taiwanese emi-
grants return to Taiwan for medical treatments as the
National Health Insurance Plan in Taiwan provides great
medical care at a lower cost.
The mechanisms underlying SPM development are
unclear; however, an association between hereditary fac-
tors, common environmental risk factors, and effects of
treatment modalities between the first and second ma-
lignancy may be responsible. In the present study, the
risk of SPMs in the small intestine, colon or rectum,
ovary, and urinary bladder was found to be higher in pa-
tients with a younger age (<50 years) at the initial diag-
nosis of uterine cancer, suggesting an underlying genetic
association. The discovery of metachronous cancers in a
young patient suggests a hereditary cause. The most
well-known example is LS, an autosomal dominant dis-
ease caused by germ-line mutations in DNA mismatch
repair genes [27, 28]. LS is associated with an increased
risk of colorectal, endometrial, and ovarian cancers, with
the risk of endometrial cancer equaling or exceeding
that of colorectal cancer. Diagnosis of gynecological can-
cer precedes colorectal cancer in over half of the women
with LS. It has been recently reported that women with
LS diagnosed with a primary endometrial cancer have anincreased risk of SPMs, including colorectal, kidney,
renal pelvic, ureteral, urinary bladder, ovarian, and breast
cancers [29, 30]. In addition to LS, patients with genetic
polymorphisms in DNA repair enzyme genes, such as
ERCC1 and XPF, have also been reported to be at an in-
creased risk of developing multiple cancers [31, 32].
The incidence of estrogen-related cancers, including
that of the breast and ovary and endometrial carcinomas
of the uterus, is rapidly increasing in Taiwan [4]. Al-
though the underlying mechanisms remain unelucidated,
they are believed to involve a complex association be-
tween genetic, endocrinal, and environmental factors.
Xenoestrogens are widely dispersed into the environ-
ment because of increasing industrialization. Marked ex-
posure levels of nonylphenol, ubiquitously found in
water supplies and food, and bisphenol A, found in con-
siderable amounts in polycarbonate plastics, can be de-
tected in the Taiwanese population. The average daily
intake of nonylphenol in Taiwan has been reported to be
4–and 8.5-folds higher than that in Germany and New
Zealand, respectively [33]. These organic compounds,
which have estrogenic effects and can cause precocious
puberty and early menarche [34], resulting in an in-
creased cumulative life-long exposure to estrogen, have
been implicated in carcinogenesis [35].
Regarding SPM sites, we found that the organs within
and closer to irradiated fields (vagina/vulva, small intes-
tine, ovary, kidney, bladder, ureter, and colorectum) were
at a higher risk of SPM than those not directly exposed to
radiation (lung and breast). Pelvic radiotherapy for endo-
metrial cancer is associated with a marked increase in the
risk of SPM in the urinary system (kidney, ureter, bladder,
and urethra), colon and rectum, vagina/vulva, sarcoma,
breast, and lung [14, 16]. Radiation has also been reported
to induce local immunosuppression which may activate
high-risk human papillomavirus infection and increase the
risk of vaginal and vulvar cancer [36, 37]. Beyond the radi-
ation field, radiotherapy may increase the risk of lung and
breast cancers through the bystander effect, in which the
non-exposed cells receive signals from irradiated cells (ra-
diation-induced genomic instability) and confer predispos-
ition to malignancy [38]. We found that the risk of
developing these SPMs was the highest within the first five
years after diagnosis of uterine cancer. Considering the
long latency required for carcinogenesis, the higher risk of
SPMs occurring within a short period after the first cancer
contradicts the hypothesis that radiotherapy is the sole
SPM initiator. Factors other than radiotherapy, such as
heritable factors, may influence the risk of SPM. Further, a
higher than expected incidence of the second cancer,
strongly associating with radiation and occurring in rela-
tively short latency periods, has been reported in numer-
ous studies about uterine corpus cancer [13, 16, 19].
However, this was not observed in our study.
Lee et al. BMC Cancer  (2015) 15:393 Page 9 of 10The major limitation of this study is the lack of infor-
mation regarding potential confounders. For example,
data on the received treatments, staging at initial diagno-
sis, and treatment-related complications were not in-
cluded. Information regarding bilateral oophorectomy is
known to influence the estimated risk of second ovarian
cancer, particularly in young patients with early stage
diseases who may have undergone hysterectomy with
ovary preservation or those who may undergo hysterec-
tomy without oophorectomy for presumed uterine my-
oma or adenomyosis prior a histological diagnosis of
malignancy. Hence, the calculated SIR of second ovarian
cancer may have been underestimated. Moreover, SIRs
in the first follow-up year were extremely high for sec-
ond ovarian and vaginal/vulvar cancers (SIR = 152.87;
95 % CI, 103.12–218.25 and SIR = 172.12; 95 % CI,
62.85–374.65, respectively Table 3). This may have been
because of a high prevalence of synchronous malignan-
cies involving anatomically related organs as 22 of 30 s
ovarian and 4 of 6 s vaginal/vulvar cancers occurred
within 6 months of diagnosis of uterine cancer.
Conclusions
The present study suggests the higher incidence of SPM in
women previously diagnosed with uterine cancer may be
because of genetic, environmental, and therapy-related fac-
tors. The overall risks and patterns of SPMs in Taiwan dif-
fer from those reported in the United States suggesting the
relative influence of each factor differs according to the pa-
tient demographics, study methodology, and follow-up
period. Therefore, surveillance guidelines for SPMs should
be developed using data specific to local populations.
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